Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy

被引：0
|
作者：
Ellsworth, Patrick [1 ,2 ]
Chen, Sheh-Li [3 ]
Key, Nigel [1 ]
Abajas, Yasmina [2 ]
Ma, Alice [1 ]
机构：
[1] Univ N Carolina, Dept Med, Div Hematol Oncol, Houpt Bldg,CB 7305,170 Manning Dr,3rd Floor, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Pediat, Div Pediat Hematol Oncol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
来源：
HAEMOPHILIA | 2021年 / 27卷 / 01期
关键词：
OBI-1; SEQUENCE; SAFETY;
D O I：
10.1111/hae.14111
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E147 / E150
页数：4
相关论文
共 33 条
  • [1] Continuous infusion of recombinant porcine factor VIII for neurosurgical management of intracranial haemorrhage in a patient with severe haemophilia A with factor VIII inhibitor
    Ruan, Gordon J.
    Mao, Jimmy J.
    Sytsma, Terin T.
    Akogyeram, Ivy I.
    Wang, Yucai
    Ashrani, Aneel A.
    Pruthi, Rajiv K.
    HAEMOPHILIA, 2020, 26 (03) : E141 - E144
  • [2] Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors
    Abou-Ismail, Mouhamed Yazan
    Vuyyala, Sowjanya
    Prunty, Jeremy
    Schmaier, Alvin H.
    Nayak, Lalitha
    HAEMOPHILIA, 2020, 26 (04) : 601 - 606
  • [3] Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
    Pfrepper, Christian
    Klamroth, Robert
    Ettingshausen, Carmen Escuriola
    Petros, Sirak
    Siegemund, Annelie
    Siegemund, Thomas
    HAEMOPHILIA, 2024, 30 (02) : 545 - 553
  • [4] Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B
    Wang, C.
    Young, G.
    HAEMOPHILIA, 2018, 24 (03) : 414 - 419
  • [5] Treatment of acquired haemophilia with recombinant porcine factor VIII: A successful strategy in a patient with unstable angina
    Owen, Mary
    Gidley, Gillian
    Horn, Elizabeth H.
    HAEMOPHILIA, 2019, 25 (02) : E94 - E97
  • [6] Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor
    Stewart, AJ
    Hanley, JP
    Ludlam, CA
    BLOOD COAGULATION & FIBRINOLYSIS, 1998, 9 : S93 - S95
  • [7] Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor
    Croteau, S. E.
    Abajas, Y. L.
    Wolberg, A. S.
    Nielsen, B. I.
    Marx, G. R.
    Baird, C. W.
    Neufeld, E. J.
    Monahan, P. E.
    HAEMOPHILIA, 2017, 23 (02) : E93 - E98
  • [8] Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study
    Rivard, G. E.
    Rothschild, C.
    Toll, T.
    Achilles, K.
    HAEMOPHILIA, 2013, 19 (03) : 449 - 455
  • [9] Successful management of refractory haematuria with recombinant porcine factor VIII replacement for paediatric congenital haemophilia A with high-titre inhibitor
    Jain, S.
    Gupta, S.
    Ambrusko, S. J.
    Shapiro, A.
    HAEMOPHILIA, 2017, 23 (04) : E358 - E361
  • [10] Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors
    Mahlangu, J. N.
    Andreeva, T. A.
    Macfarlane, D. E.
    Walsh, C.
    Key, N. S.
    HAEMOPHILIA, 2017, 23 (01) : 33 - 41
1234